Show simple item record

dc.contributor.authorFletcher, Andrew
dc.contributor.authorChoudhury, Ananya
dc.contributor.authorAlam, Nooreen
dc.date.accessioned2012-03-20T12:49:16Z
dc.date.available2012-03-20T12:49:16Z
dc.date.issued2011
dc.identifier.citationMetastatic bladder cancer: a review of current management. 2011, 2011:545241 ISRN Urolen_GB
dc.identifier.issn2090-5815
dc.identifier.pmid22084801
dc.identifier.doi10.5402/2011/545241
dc.identifier.urihttp://hdl.handle.net/10541/216113
dc.description.abstractBladder cancer continues to result in substantial morbidity and mortality for affected individuals. Advances in the management of metastatic bladder cancer have been limited. Chemotherapy with platinum-based regimes remains the mainstay of first-line treatment. Studies investigating alternative regimes have offered no survival advantage. Targeted therapies may offer benefit either as single agent or in combination with chemotherapy. Symptoms due to metastatic bladder cancer impact patients' quality of life, and therefore holistic management is vital. Such management includes radiotherapy, bisphosphonates, and the involvement of specialist palliative care services. This review will discuss the current management for metastatic bladder cancer, future potential treatment modalities, and the evidence to support the management strategies.
dc.language.isoenen
dc.rightsArchived with thanks to ISRN urologyen_GB
dc.titleMetastatic bladder cancer: a review of current management.en
dc.typeArticleen
dc.contributor.departmentDepartment of Palliative and Supportive Care, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK.en_GB
dc.identifier.journalISRN Urologyen_GB
html.description.abstractBladder cancer continues to result in substantial morbidity and mortality for affected individuals. Advances in the management of metastatic bladder cancer have been limited. Chemotherapy with platinum-based regimes remains the mainstay of first-line treatment. Studies investigating alternative regimes have offered no survival advantage. Targeted therapies may offer benefit either as single agent or in combination with chemotherapy. Symptoms due to metastatic bladder cancer impact patients' quality of life, and therefore holistic management is vital. Such management includes radiotherapy, bisphosphonates, and the involvement of specialist palliative care services. This review will discuss the current management for metastatic bladder cancer, future potential treatment modalities, and the evidence to support the management strategies.


This item appears in the following Collection(s)

Show simple item record